Pohanka_2008_Neuro.Endocrinol.Lett_29_755

Reference

Title : New performance of biosensor technology for Alzheimer's disease drugs: in vitro comparison of tacrine and 7-methoxytacrine - Pohanka_2008_Neuro.Endocrinol.Lett_29_755
Author(s) : Pohanka M , Kuca K , Kassa J
Ref : Neuro Endocrinol Lett , 29 :755 , 2008
Abstract :

Two drugs were tested using electrochemical biosensor with immobilized acetylcholinesterase (AChE). The first was commercialized drug tacrine (known also as Cognex) used for treatment of cognitive manifestation of Alzheimer\'s disease (AD). The second one was its 7-methoxy derivate (7-MEOTA) that has not been marketed. We determined the IC50 (6.67+/-0.92)x10-7 M for tacrine and (1.66+/-1.43)x10-9 M for 7-MEOTA. In this in vitro study, 7-MEOTA acts as stronger inhibitor of AChE and in this way could be more favorable for treatment of cognitive manifestation of AD. Our study shows that biosensor technology could be used as a quick and cheap tool for testing of promising AChE inhibitors (AD drug candidates).

PubMedSearch : Pohanka_2008_Neuro.Endocrinol.Lett_29_755
PubMedID: 18987590

Related information

Citations formats

Pohanka M, Kuca K, Kassa J (2008)
New performance of biosensor technology for Alzheimer's disease drugs: in vitro comparison of tacrine and 7-methoxytacrine
Neuro Endocrinol Lett 29 :755

Pohanka M, Kuca K, Kassa J (2008)
Neuro Endocrinol Lett 29 :755